Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Gene transfer for ischemic cardiovascular disease: is this the end of the beginning or the beginning of the end?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 138–144 (2005)Cite this article

Abstract

The past decade has represented a period of high expectations for cardiovascular gene transfer on the basis of the findings from preclinical experiments and promising early clinical results. Yet, randomized studies have not demonstrated similar results. Do these poor results mean that gene transfer for ischemic cardiovascular disease has failed in its promise, or do they merely signify the inherent challenges of a pioneering field? In this paper we briefly review the clinical experience of gene transfer for ischemic cardiovascular disease and propose future directions for research.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389

  2. Serruys PW et al. (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331: 489–495

    Article  CAS  Google Scholar 

  3. Fischman DL et al. (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331: 496–501

    Article  CAS  Google Scholar 

  4. Isner JM et al. (2001) Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 89: 389–400

    Article  CAS  Google Scholar 

  5. Nabel EG et al. (1989) Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 244: 1342–1344

    Article  CAS  Google Scholar 

  6. Wilson JM et al. (1989) Implantation of vascular grafts lined with genetically modified endothelial cells. Science 244: 1344–1346

    Article  CAS  Google Scholar 

  7. Simari R et al. (1996) Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 98: 225–235

    Article  CAS  Google Scholar 

  8. Yanagisawa-Miwa A et al. (1992) Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257: 1401–1403

    Article  CAS  Google Scholar 

  9. Cross MJ and Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22: 201–207

    Article  CAS  Google Scholar 

  10. Tsurumi Y et al. (1996) Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 94: 3281–3290

    Article  CAS  Google Scholar 

  11. Isner JM et al. (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348: 370–374

    Article  CAS  Google Scholar 

  12. Baumgartner I et al. (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114–1123

    Article  CAS  Google Scholar 

  13. Baumgartner I et al. (2000) Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132: 880–884

    Article  CAS  Google Scholar 

  14. Isner JM et al. (1998) Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 28: 964–973

    Article  CAS  Google Scholar 

  15. Shyu KG et al. (2003) Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 114: 85–92

    Article  CAS  Google Scholar 

  16. Makinen K et al. (2002) Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 6: 127–133

    Article  CAS  Google Scholar 

  17. Rajagopalan S et al. (2002) Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 90: 512–516

    Article  CAS  Google Scholar 

  18. Rajagopalan S et al. (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933–1938

    Article  CAS  Google Scholar 

  19. Comerota AJ et al. (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35: 930–936

    Article  Google Scholar 

  20. Morishita R et al. (2004) Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44: 203–209

    Article  CAS  Google Scholar 

  21. Rajagopalan S et al. (2004) Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease. Hum Gene Ther 15: 619–24

    Article  CAS  Google Scholar 

  22. Laitinen M et al. (1998) Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 9: 1481–1486

    Article  CAS  Google Scholar 

  23. Freedman SB et al. (2002) Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA. Hum Gene Ther 13: 1595–1603

    Article  CAS  Google Scholar 

  24. Losordo DW et al. (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98: 2800–2804

    Article  CAS  Google Scholar 

  25. Symes JF et al. (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68: 830–836

    Article  CAS  Google Scholar 

  26. Vale PR et al. (2000) Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102: 965–974

    Article  CAS  Google Scholar 

  27. Sarkar N et al. (2001) Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: angiogenic gene therapy. J Intern Med 250: 373–381

    Article  CAS  Google Scholar 

  28. Kolsut P et al. (2003) Gene therapy of coronary artery disease with phvegf165—early outcome. Kardiol Pol 59: 373–384

    PubMed  Google Scholar 

  29. Huwer H et al. (2001) Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease. Eur J Cardiothorac Surg 20: 1128–134

    Article  CAS  Google Scholar 

  30. Lathi KG et al. (2001) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 92: 19–25

    Article  CAS  Google Scholar 

  31. Vale PR et al. (1999) Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping. J Am Coll Cardiol 34: 246–254

    Article  CAS  Google Scholar 

  32. Vale PR et al. (2001) Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103: 2138–2143

    Article  CAS  Google Scholar 

  33. Losordo DW et al. (2002) Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105: 2012–2018

    Article  CAS  Google Scholar 

  34. Losordo DW and Dimmeler S (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation 109: 2487–2491

    Article  Google Scholar 

  35. Rosengart TK et al. (1999) Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100: 468–474

    Article  CAS  Google Scholar 

  36. Giordano FJ et al. (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 2: 534–539

    Article  CAS  Google Scholar 

  37. Grines C et al. (2002) Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105: 1291–1297

    Article  CAS  Google Scholar 

  38. Grines CL et al. for the Angiogenic GENe Therapy (AGENT-2) Study Group (2003) A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 42: 1339–1347

    Article  CAS  Google Scholar 

  39. Ueda H et al. (1999) Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart. Ann Thorac Surg 67: 1726–1731

    Article  CAS  Google Scholar 

  40. Zhong J et al. (2003) Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest 112: 30–41

    Article  CAS  Google Scholar 

  41. Shyu KG et al. (2002) Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 54: 576–583

    Article  CAS  Google Scholar 

  42. Green LA et al. (2002) Indirect monitoring of endogenous gene expression by positron emission tomography (PET) imaging of reporter gene expression in transgenic mice. Mol Imaging Biol 4: 71–81

    Article  Google Scholar 

  43. Wu JC et al. (2002) Optical imaging of cardiac reporter gene expression in living rats. Circulation 105: 1631–1634

    Article  Google Scholar 

  44. Wu JC et al. (2004) Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation 110: 685–691

    Article  CAS  Google Scholar 

  45. Peng KW et al. (2002) Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 8: 527–531

    Article  CAS  Google Scholar 

  46. Baker AH (2004) Designing gene delivery vectors for cardiovascular gene therapy. Prog Biophys Mol Biol 84: 279–299

    Article  CAS  Google Scholar 

  47. Losordo DW and Dimmeler S (2004) Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation 109: 2692–2697

    Article  Google Scholar 

  48. Ikeda Y et al. (2004) Development of angiogenic cell and gene therapy by transplantation of umbilical cord blood with vascular endothelial growth factor gene. Hypertens Res 27: 119–128

    Article  CAS  Google Scholar 

  49. Askari A et al. (2004) Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy. J Am Coll Cardiol 43: 1908–1914

    Article  CAS  Google Scholar 

  50. Iwaguro H et al. (2002) Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105: 732–738

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Diseases and Internal Medicine,

    Sorin V Pislaru & Robert D Simari

  2. Division of Cardiovascular Diseases and Internal Medicine,

    Sorin V Pislaru & Robert D Simari

  3. Mayo Clinic College of Medicine, Rochester, MN, USA

    Sorin V Pislaru & Robert D Simari

Authors
  1. Sorin V Pislaru
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert D Simari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert D Simari.

Ethics declarations

Competing interests

Robert D Simari is an investigator in the AGENT 3 study (sponsored by Berlex Pharmaceuticals) and an investigator and a steering committee member in the GENASIS study (sponsored by Corautus Inc.)

Glossary

RUTHERFORD CLASS

Rutherford grading is based on clinical findings of limb ischemia (grade I, claudication; grade II, rest pain; grade III, tissue loss)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pislaru, S., Simari, R. Gene transfer for ischemic cardiovascular disease: is this the end of the beginning or the beginning of the end?. Nat Rev Cardiol 2, 138–144 (2005). https://doi.org/10.1038/ncpcardio0136

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0136

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing